Get started

Biotechnology

DVAX- Is Approaching A Critical Level: 50%/120% potential profitDVAX - Is Approaching A Critical Level: DVAX- Is Approaching A Critical Level: 50%/120% potential profit Here’s A Way to Play It. see chart info: DVAX Dynavax Technologies Corporation Healthcare | Biotechnology | USA NEWS for Dynavax Technologies Corporation : as of August 13, 2020 www.fool.com finance.yahoo.com DISCLAIMER: Futures, stocks and options trading involves substantial risk of loss and is not suitable for every investor. The valuation of futures, stocks and options may fluctuate, and, as a result, may lose more than their original investment. All trading strategies , CHART are used at your own risk. ...
NASDAQ:DVAXLong
by Voxeurh514
SESEN BIO: Buy opportunity/ emerging Golden Cross.Sesen Bio Inc has turned overbought on the 1D chart (RSI = 86.656, MACD = 0.058, ADX = 57.197) after a strong 10 day bullish sequence that broke above both the 1D MA50 and MA200 periods, but remains a buy opportunity as the MACD remains below the 9-month High. On top of that we have an emerging Golden Cross, while the price seems to be still within the Accumulation Phase. Our short-term Target is 1.500, while if the Lower Highs trend-line breaks, we will re-buy for a 2.500 Target. ** If you like our free content follow our profile to get more daily ideas. ** Comments and likes are greatly appreciated.
SLong
by InvestingScope
3
Biotech Channel 7/18/2020I've noticed that most tech related ETFs and the NQ are in the same general channel. This is the XBI at the 4 hour view. It's the biotech ETF. As you may see, my buy zone is way below. This may be due to the coronavirus vaccine hype. Not sure. Either way, biotech has been grinding at the top of my channel for a while. If it pops above it, it will likely get hammered down. I'll short it if it pops above my channel and go long when it gets hammered down to my buy zone.
AMEX:XBI
by Itsallsotiresome
2
MGNX was aquarterly gainer,rising+433.64%.Expect Uptrend reversaMacrogenics (MGNX, $28.87) was one of top quarterly gainers, jumping +433.64% to $28.87 per share. Tickeron A.I.dvisor analyzed 379 stocks in the Biotechnology Industry over the last three months, and discovered that 352 of them (92.98%) charted an Uptrend while 27 of them (7.02%) trended down. Tickeron A.I.dvisor found 287 similar cases when MGNX's price went up 15% within three months. In 208 out of those 287 cases, MGNX's price went down during the following month. Based on these historical data, Tickeron A.I. thinks the odds of an Uptrend reversal for MGNX are 72%. The higher Bollinger Band was broken -- a price fall is expected as the ticker heads toward the middle band, which invites the trader to consider selling or shorting the ticker, or exploring put options. In 37 of 41 cases where MGNX's price broke its higher Bollinger Band, its price dropped further during the following month. The odds of a continued Downtrend are 90%.
NASDAQ:MGNXShort
by AlTorress
PARADIGM - 160% PROFIT TO CONTINUEPay close attention to PARADIGM (PAR). 3 Potential Moves 1. We bounce off the .382 Fib level and return to test the 2.80 mark which we saw on 11/05/20 -Being the end of the trading week I suspect the latter. 2. We break the .382 Fib level and Uptrend and head for the 'Golden Pocket' -Bounce off strong support at 2.00 mark -MACD is starting to squeeze but if we find momentum next week we could start to spread again. -PAR loves the .5 Fibonacci Retracement level. (Short term fact) -We hit the deeper uptrend and continue back up towards the 2.80 mark to test a strong EQ Resistance Level. Very Possible -It regains buyer momentum in the 'Golden Pocket' between the .5-.618 Fib Level. Very Possible -Positive news released early next week bring strong buying sentiment back into the market and create an Higher Low ready for the next leg up. 3. We BREAK both uptrend trendlines creating NEW Bearish Market Structure and head for the next Major Support @ 1.48 Another company im keeping a close eye on. PARADIGM BIOPHARMACEUTICALS LTD is a late stage drug development company with their aim to treat musculoskeletal disorders in humans with degenerative disease driven by injury, viral infection, aging or genetic predisposition. They have a cash balance sheet of $108 Million (06/04/20), FDA Approval, IP Protection & Patents, Agreements that stand for 20 years regarding manufacturing, Fully funded until 2022. EYES ON!!! These Ideas are NOT 'Financial Advice'!. Scenarios are based off a mixture of TA and Fundamentals current at the time. All IMO GLTAH. Happy Hunting!!!
ASX:PAR
by Trader_Johnni
3
MRNA was a top gainer,rising 106.32%.Expect Uptrend continuationModerna (MRNA, $62) was one of top quarterly gainers, jumping +106.32% to $62 per share. Tickeron A.I.dvisor analyzed 380 stocks in the Biotechnology Industry over the last three months, and discovered that 357 of them (94.07%) charted an Uptrend while 23 of them (5.93%) trended down. Tickeron A.I.dvisor found 135 similar cases when MRNA's price jumped over 15% within three months. In 84 out of those 135 cases, MRNA's price went up during the following month. Based on these historical data, Tickeron A.I. thinks the odds of an Uptrend continuation for MRNA are 62%.
NASDAQ:MRNALong
by AlTorress
Wall Street is Short VBIV, but I'm Long *Target: [$3.50]*Link to Culper Research report that states they are shorting VBIV because the company is "worthless" img1.wsimg.com First, it's always important to consider ALL information. It's also important to be transparent about knowledge. If you are going to make any VBIV trades you really should read the entire report. 1) I think many of the points made in the Culper Report are legitimate 2) I am not as optimistic about long term price targets as those seen at Guggenheim and on yahoo finance 3) I still believe this is a good short-term trade based on sentiment and momentum regarding June 22-24 release of clinical glioblastoma data Stop loss @ $2.04
VLong
by jfs2152
5
Novavax (NVAX) stock price is on track...for now [LONG]Just re-iterating my previous assertion (guess) that NVAX is on course for massive gains in the long-term. Doesn't mean it's a great company but this pandemic has initiated a similar pattern in the past. They have several great developments in the works: NanoFlu, RSV F, and a COVID-19 vaccine candidate. See my previous posts especially the related one. This is purely speculation based on their pipeline. This is not financial advice.
NASDAQ:NVAXLong
by traderman001
3
PFNX Aroon Indicator entered an Uptrend on June 23, 2020.Over the last three days, Tickeron AI has detected that PFNX's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red line stays below 30, this is an indicator that the stock could be poised for a strong Uptrend. For traders, this could mean going long the stock or exploring call options in the next month. Tickeron A.I.dvisor backtested this indicator and found 150 similar cases, 135 of which were successful. Based on this data, the odds of success are 90%.
PLong
by AlTorress
FPRX was a top gainer,rising +132.36%.Expect an Uptrend reversalFive Prime Therapeutics (FPRX, $6.39) was one of top quarterly gainers, jumping +132.36% to $6.39 per share. Tickeron A.I.dvisor analyzed 380 stocks in the Biotechnology Industry over the last three months, and discovered that 356 of them (93.72%) charted an Uptrend while 24 of them (6.28%) trended down. Tickeron A.I.dvisor found 279 similar cases when FPRX's price went up 15% within three months. In 201 out of those 279 cases, FPRX's price went down during the following month. Based on these historical data, Tickeron A.I. thinks the odds of an Uptrend reversal for FPRX are 72%.
FLong
by AlTorress